Epigenomics AG
Epigenomics AG
- Market cap
- $982.18K
Your view on EPGNF
Overview
What the company does, where it operates, and who runs it.
About Epigenomics AG
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Noel Thomas Doheny
- Headquarters
- Geneststrasse 5, Heidelberg, DE
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Noel Thomas Doheny
- Headquarters
- Geneststrasse 5, Heidelberg, DE
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China.
The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Epigenomics AG. Starting points for Epigenomics AG: EPS -$0.36, beta 0.77 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Epigenomics AG. Epigenomics AG does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Epigenomics AG. Trailing twelve-month EPS for Epigenomics AG stands at -$0.36. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current YearFY Dec 2016 | Next YearFY Dec 2017 |
|---|---|---|
| Avg. estimate | −EUR 76.59 | −EUR 79.79 |
| Low estimate | −EUR 76.59 | −EUR 79.79 |
| High estimate | −EUR 76.59 | −EUR 79.79 |
| No. of analysts | 1 | 1 |
| Year-ago EPS | — | — |
| Growth | — | — |
Revenue Estimate
| Revenue | Current YearFY Dec 2016 | Next YearFY Dec 2017 |
|---|---|---|
| Avg. estimate | EUR 4.37M | EUR 1.25M |
| Low estimate | EUR 4.37M | EUR 1.25M |
| High estimate | EUR 4.37M | EUR 1.25M |
| No. of analysts | 1 | 1 |
| Year-ago revenue | — | — |
| Growth | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Epigenomics AG. Epigenomics AG has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| BMMJBody and Mind Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $14,769 | ||
| CHMEChina Medicine Corporation | Healthcare | Medical - Pharmaceuticals | $829,922 | ||
| CHYPFHealth Logic Interactive Inc. | Healthcare | Medical - Devices | $165,839 | ||
| NGMCNext Generation Management Corp. | Industrials | Specialty Business Services | $717 | ||
| NSTMNovelStem International Corp. | Healthcare | Medical - Diagnostics & Research | $653,997 | ||
| PCYNProcyon Corporation | Healthcare | Drug Manufacturers - Specialty & Generic | $1.5M | ||
| PPJEPPJ Healthcare Enterprises, Inc. | Healthcare | Medical - Healthcare Information Services | $890,484 | ||
| RSHNRushNet, Inc. | Healthcare | Medical - Diagnostics & Research | $857,642 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| DRIODarioHealth Corp. | Healthcare | NASDAQ | $16.5M | ||
| FEEDENvue Medical, Inc. | Healthcare | NASDAQ | $951,429 | ||
| GENXGenex Pharmaceutical, Inc. | Healthcare | OTC | $1,788 | ||
| HLTHQCue Health Inc. | Healthcare | OTC | $159 | ||
| IDTAIDenta Corp. | Healthcare | OTC | $1.1M | ||
| IMR.AXImricor Medical Systems, Inc. | Healthcare | ASX | — | ||
| ITOCiTonic Holdings Ltd. | Healthcare | NASDAQ | $10.7M | ||
| KKURChromoCure, Inc. | Healthcare | OTC | $8,200 | ||
| LABStandard BioTools Inc. | Healthcare | NASDAQ | $225.0M | ||
| LANZLancer Orthodontics, Inc. | Healthcare | OTC | $74,488 | ||
| LDX.AXLumos Diagnostics Holdings Limited | Healthcare | ASX | — | ||
| LDXHFLumos Diagnostics Holdings Limited | Healthcare | OTC | $158.6M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Epigenomics AG. Coverage tracks Epigenomics AG within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Epigenomics AG.